Lisata Therapeutics (LSTA) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.
Financial details weren't disclosed.
The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.
The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.
Price: 2.77, Change: +0.02, Percent Change: +0.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.